Excipients determine whether a peptide survives its own formulation, and the choice is usually driven by the specific degradation pathway you are trying to block.
Key Takeaways
- Buffer selection sets the pH at which the peptide is most stable, which is usually away from its isoelectric point.
- Polysorbates and poloxamers compete with the peptide for the air-water and solid-water interfaces, which is where much aggregation begins.
- For injectable or nasal formats, tonicity agents and preservatives are required for multi-dose presentations.
Buffers and pH control
Buffer selection sets the pH at which the peptide is most stable, which is usually away from its isoelectric point. Histidine, citrate, and phosphate are common, and the choice interacts with any freeze-drying step and with the intended route.
Stabilisers and bulking agents
Sugars such as sucrose and trehalose stabilise proteins and peptides during drying through water replacement and glass formation. Mannitol and glycine serve as bulking agents that give a lyophilised cake acceptable structure.
For related mechanism work, see peptide PEGylation.
Surfactants and interfacial damage
Polysorbates and poloxamers compete with the peptide for the air-water and solid-water interfaces, which is where much aggregation begins. Their inclusion is standard practice even at low concentration, though degradation of the surfactant itself must be monitored.
Antioxidants and chelators
Where oxidation is the dominant pathway, methionine or ascorbate can act as sacrificial antioxidants and EDTA can remove trace metal catalysts. EDTA is incompatible with metallopeptides such as copper complexes and must be avoided there.
Tonicity and preservatives
For injectable or nasal formats, tonicity agents and preservatives are required for multi-dose presentations. Each additional component is another compatibility variable, so the excipient list should be justified rather than inherited.
Experimental Conditions and Practical Setup
Excipients are screened at the intended formulation pH and concentration, held under stress, and compared against a no-excipient control analysed by both size-exclusion and reversed-phase methods. Using both readouts matters because an excipient can suppress aggregation while accelerating chemical degradation, and neither assay alone would reveal that.
Excipient classes and the failure each addresses
| Class | Examples | Addresses |
|---|---|---|
| Buffers | Histidine, citrate, phosphate | pH-driven degradation |
| Stabilisers | Sucrose, trehalose | Drying and storage stress |
| Bulking agents | Mannitol, glycine | Cake structure |
| Surfactants | Polysorbate 20/80, poloxamer | Interfacial aggregation |
| Chelators | EDTA | Metal-catalysed oxidation, but strips metallopeptides |
Practical Notes for the Bench
- Never add EDTA to metallopeptide formulations such as copper complexes.
- Justify each excipient rather than copying an inherited formulation.
- Monitor surfactant degradation as part of the stability programme.
Frequently Asked Questions
Which excipient matters most?
The buffer, because it sets the pH, and pH drives most peptide degradation pathways.
Why are surfactants included?
They compete for interfaces where aggregation typically begins, even when used at low concentration.
Is EDTA always safe?
No. It chelates the metal out of metallopeptides such as GHK-Cu and will destroy the active complex.
Can EDTA be added to any peptide formulation?
No. It will strip the metal from metallopeptides such as copper complexes, destroying the active species. Check whether a bound metal is required before including it.
Related Reading
- peptide PEGylation
- transdermal peptide delivery
- peptide lyophilisation
- GHK-Cu copper peptide
- cell-penetrating peptides
References & Further Reading
- Schaal Z et al. Impact of spin-freezing parameters and excipient composition on product stability of a PEGylated peptide formulation. Int J Pharm. 2025. PubMed 40759220
- Lipiäinen T et al. Formulation and stability of cytokine therapeutics. J Pharm Sci. 2015. PubMed 25492409
- Peptide literature search on PubMed
- Full-text archive at PubMed Central
- Peptide research collection at Nature
This article summarises published research practice for laboratory professionals. It is not a guide to human use, and no claim of therapeutic benefit is made or implied.
Reviewed by Priya Raghunathan, MSc, Formulation & Stability Science.